SUTRO BIOPHARMA INC (STRO) competitors & alternatives
Health Care · NASDAQ
SUTRO BIOPHARMA INC (STRO)'s top competitors and alternatives — its most similar public companies — include Alnylam Pharmaceuticals (ALNY), CORBUS PHARMACEUTICALS HOLDINGS IN (CRBP), WHITEHAWK THERAPEUTICS INC (WHWK), Exelixis (EXEL), Summit Therapeutics (SMMT), KARYOPHARM THERAPEUTICS INC (KPTI), BridgeBio Oncology Therapeutics, Inc. (BBOT), Amgen (AMGN), Pyxis Oncology, Inc. (PYXS), MACROGENICS INC (MGNX), ADC THERAPEUTICS SA (ADCT) and ZYMEWORKS INC (ZYME). These are SUTRO BIOPHARMA INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top STRO competitors & alternatives
-
Alnylam PharmaceuticalsALNYHealth Care
Alnylam is a global leader in RNA interference therapeutics, pioneering a new class of genetic medicines to treat rare and serious diseases.
$266.99 (as of 2026-07-22) · market cap $36.2B
-
CORBUS PHARMACEUTICALS HOLDINGS INCRBPHealth Care
Clinical-stage biopharmaceutical company developing next-generation antibody drug conjugates for oncology and a CB1 receptor inverse agonist for obesity.
$8.84 (as of 2026-07-22) · market cap $163M
-
WHITEHAWK THERAPEUTICS INCWHWKHealth Care
Clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) targeting validated tumor antigens with advanced linker-payload…
$3.99 (as of 2026-07-22) · market cap $216M
-
ExelixisEXELHealth Care
Exelixis is a profitable oncology company commercializing the multi-kinase inhibitor cabozantinib across multiple cancer indications while advancing a pipeline…
$54.98 (as of 2026-07-22) · market cap $14.0B
-
Summit TherapeuticsSMMTHealth Care
Oncology-focused biotech developing ivonescimab, a first-in-class bispecific antibody combining PD-1 immunotherapy with anti-VEGF anti-angiogenesis, with Phase…
$14.74 (as of 2026-07-22) · market cap $11.4B
-
KARYOPHARM THERAPEUTICS INCKPTIHealth Care
Karyopharm is a clinical-stage oncology company commercializing XPOVIO, a first-in-class XPO1 inhibitor for multiple myeloma, with ongoing trials in…
$7.18 (as of 2026-07-22) · market cap $178M
-
BridgeBio Oncology Therapeutics, Inc.BBOTHealth Care
BridgeBio Oncology is advancing next-generation small-molecule inhibitors of RAS and PI3K pathways for previously untreatable solid tumors including…
$8.90 (as of 2026-07-22) · market cap $701M
-
AmgenAMGNHealth Care
A global biotechnology innovator producing biologics, monoclonal antibodies, and small molecules across oncology, cardiovascular, inflammation, and bone…
$366.05 (as of 2026-07-22) · market cap $197.7B
-
Pyxis Oncology, Inc.PYXSHealth Care
Pyxis Oncology is a clinical-stage biopharma developing innovative antibody-drug conjugates (ADCs) that target the tumor microenvironment to improve efficacy…
$2.53 (as of 2026-07-22) · market cap $160M
-
MACROGENICS INCMGNXHealth Care
Clinical-stage biopharmaceutical company developing innovative antibody-based cancer therapeutics using proprietary DART, TRIDENT, and ADC platforms.
$4.30 (as of 2026-07-22) · market cap $289M
-
ADC THERAPEUTICS SAADCTHealth Care
ADC Therapeutics develops antibody-drug conjugates (ADCs) targeting hematologic and solid tumors, with its lead product ZYNLONTA commercialized for lymphoma.
$1.24 (as of 2026-07-22) · market cap $158M
-
ZYMEWORKS INCZYMEHealth Care
A biotech company pioneering multispecific antibodies and ADCs for cancer and autoimmune disease, monetizing through a partnership-driven royalty aggregation…
$23.36 (as of 2026-07-22) · market cap $1.7B
Not quite? Describe exactly what you want →
Peers are SUTRO BIOPHARMA INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: SUTRO BIOPHARMA INC (STRO).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.